Revolution Medicines (RVMD)
NASDAQ:RVMD
Want to see RVMD full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-1.92Last Year’s EPS
-1.31Same Quarter Last Year
Strong Buy
Based on 20 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed overwhelmingly positive clinical and strategic progress—most notably the practice‑changing RASolute 302 Phase III result (60% reduction in risk of death) and a large capital raise that materially strengthens the balance sheet—while candidly disclosing near‑term financial impacts from rapid program acceleration, elevated stock‑based compensation and higher operating expenses. Operational and regulatory timing uncertainties and trial design complexities were noted, but the program momentum, supportive data across multiple assets, and strong funding availability suggest the positives materially outweigh the headwinds.Company Guidance
Transformative Phase III RASolute 302 Results (daraxonrasib)
Daraxonrasib monotherapy met primary and key secondary endpoints in RASolute 302, demonstrating a 60% reduction in risk of death versus chemotherapy in previously treated metastatic pancreatic cancer and a median overall survival exceeding 1 year; treatment was generally well tolerated with no new safety signals.
Strong Early‑Line and Combination Signals
Phase I/II data presented at AACR showed encouraging durability: daraxonrasib monotherapy 6‑month Kaplan‑Meier estimates PFS 71% and OS 83%; daraxonrasib + gemcitabine/nab‑paclitaxel 6‑month PFS 84% and OS 90%, supporting advancement of first‑line registrational programs (RASolute 303).
Compelling Zoldonrasib Activity in NSCLC (G12D)
Zoldonrasib monotherapy in previously treated NSCLC demonstrated a confirmed objective response rate (ORR) of 52%, disease control rate (DCR) of 93%, median progression‑free survival (PFS) of 11.1 months and an estimated 12‑month survival of 73% (median OS immature), supporting upcoming registrational trials including RASolve 308.
Extensive Registrational and Pipeline Advancement
Multiple registrational studies advancing or initiated: RASolute 303 (1L daraxonrasib mono + combo), RASolute 304 (adjuvant), RASolute 305 (zoldonrasib + chemo), RASolute 309 (doublet combo planned H2 2026), RASolve 301 (previously treated NSCLC) expanded, and RMC‑5127 (G12V) FIH ongoing with recommended Phase II dose expected in H2 2026.
New Catalytic RAS(ON) Class (RM‑055) with Preclinical Activity
Preclinical RM‑055 (catalytic RAS(ON) inhibitor) produced robust, durable regressions across KRAS G12 mutant xenograft models, including models resistant to prior RAS inhibitors; first‑in‑human study on track for Q4 2026.
Significant Capital Raise and Strong Pro Forma Cash Position
Company completed an historic $2.0 billion dual‑tranche capital raise; ended Q1 2026 with $1.9 billion in cash and investments and subsequently received $2.1 billion net proceeds from offerings in April, providing roughly $4.0 billion pro forma cash to fund operations and accelerate programs.
Regulatory and Access Progress
Company intends to submit an NDA under the FDA Commissioner’s National Priority Voucher Program, received FDA 'safe‑to‑proceed' letter to initiate an expanded access protocol in the U.S., and RASolute 302 to be featured in ASCO plenary—accelerating regulatory engagement and patient access planning.
Commercial and Global Launch Readiness
Built commercialization infrastructure, onboarding U.S. field teams (medical affairs, market access, sales), appointed regional general managers for APAC, Japan and Germany, and report launch readiness planning for U.S. and priority international markets.
Increased Statistical Power for NSCLC Program
RASolve 301 (previously treated NSCLC) enrollment expanded from 420 to 590 patients (≈40% increase) to boost statistical power for the overall survival component of the dual primary endpoint; enrollment said to be progressing well with substantial completion expected this year.
RVMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RVMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $151.07 | $142.51 | -5.67% |
Feb 25, 2026 | $103.24 | $102.15 | -1.06% |
Nov 05, 2025 | $59.34 | $61.38 | +3.44% |
Aug 06, 2025 | $36.67 | $34.95 | -4.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Revolution Medicines (RVMD) report earnings?
Revolution Medicines (RVMD) is schdueled to report earning on Aug 12, 2026, After Close (Confirmed).
What is Revolution Medicines (RVMD) earnings time?
Revolution Medicines (RVMD) earnings time is at Aug 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RVMD EPS forecast?
RVMD EPS forecast for the fiscal quarter 2026 (Q2) is -1.92.
